Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed the Final (28 day) follow-up visit in Study ALX0681-C301.~2. \>= 18 years of age at the time of signing the informed consent form.~3. Provided informed consent prior to initiation of any study specific activity/procedure.~Exclusion Criteria:~1. Not being able/willing to comply with the study protocol procedures.~2. Currently enrolled in a clinical study with another investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- caplacizumab (Type: EXPERIMENTAL): Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange \[PE\], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product \[IMP\], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.

Based on this trial design, predict the completion outcome and termination type (if applicable).